
Profitability, historical returns, and peer comparisons.
According to Ascendis Pharma A/S’s latest financial reports and current stock price. The company's current ROE is 190.44%. This represents a change of 278.86% compared to the average of 50.27% of the last 4 quarters.
The mean historical ROE of Ascendis Pharma A/S over the last ten years is 32.00%. The current 190.44% ROE has changed 495.23% with respect to the historical average. Over the past ten years (40 quarters), ASND's ROE was at its highest in in the September 2023 quarter at 220.91%. The ROE was at its lowest in in the June 2023 quarter at -187.28%.
Average
32.00%
Median
-41.10%
Minimum
-221.45%
Maximum
357.68%
Discovering the peaks and valleys of Ascendis Pharma A/S ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 410.16%
Maximum Annual ROE = 357.68%
Minimum Annual Increase = -249.22%
Minimum Annual ROE = -221.45%
| Year | ROE | Change |
|---|---|---|
| 2025 | 134.58% | -62.37% |
| 2024 | 357.68% | 8.24% |
| 2023 | 330.44% | -249.22% |
| 2022 | -221.45% | 410.16% |
| 2021 | -43.41% | -13.10% |
| 2020 | -49.95% | 36.81% |
| 2019 | -36.51% | -21.40% |
| 2018 | -46.45% | -29.81% |
| 2017 | -66.18% | 70.62% |
| 2016 | -38.79% | 41.77% |
The current ROE of Ascendis Pharma A/S (ASND) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
274.23%
5-year avg
111.57%
10-year avg
32.00%
Ascendis Pharma A/S’s ROE is greater than Xeris Biopharma Holdings, Inc. (-426.33%), greater than Septerna Inc (-6.31%), greater than MBX Biosciences, Inc. Common Stock (-26.01%), greater than BioMarin Pharmaceutical Inc. (-0.31%), less than Ultragenyx Pharmaceutical Inc. (213.22%), less than Corcept Therapeutics Incorporated (22.94%), less than Neurocrine Biosciences, Inc. (19.74%), greater than Stoke Therapeutics, Inc. (-67.30%), greater than Insmed Incorporated (-82.75%), less than United Therapeutics Corporation (19.18%),
| Company | ROE | Market cap |
|---|---|---|
| -426.33% | $1.91B | |
| -6.31% | $2.23B | |
| -26.01% | $2.53B | |
| -0.31% | $11.06B | |
| 213.22% | $1.69B | |
| 22.94% | $8.56B | |
| 19.74% | $16.81B | |
| -67.30% | $1.77B | |
| -82.75% | $24.13B | |
| 19.18% | $26.10B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ascendis Pharma A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ascendis Pharma A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Ascendis Pharma A/S's ROE?
How is the ROE calculated for Ascendis Pharma A/S (ASND)?
What is the highest ROE for Ascendis Pharma A/S (ASND)?
What is the 3-year average ROE for Ascendis Pharma A/S (ASND)?
What is the 5-year average ROE for Ascendis Pharma A/S (ASND)?
How does the current ROE for Ascendis Pharma A/S (ASND) compare to its historical average?